February 19, 2025
London-Based Healthtech Startup Level Zero Health Secures $6.9M Pre-Seed Funding To Pioneer Real-Time Hormone Monitoring
London, England –
Level Zero Health, leveraging advanced DNA-based sensors for real-time hormone monitoring, has secured an oversubscribed £5.5M ($6.9M) in a pre-seed funding round. Announced on February 18, 2025, the round was led by Swiss venture capital firm Redalpine, with support from HAX (SOSV), Entrepreneur First, and several industry experts. This investment will drive the development of the company’s pioneering continuous hormone monitoring device, a first-of-its-kind innovation set to revolutionize hormonal health diagnostics and management.
About Level Zero Health
Founded in 2023 by Ula Rustamova and Irene Jia and based in both London and San Francisco, Level Zero Health is pioneering wearable patch that uses DNA-based sensors to monitor hormones like cortisol, progesterone, estrogen, and testosterone in real time. By providing continuous and non-invasive hormone monitoring, the startup is aiming to make hormone diagnostics more accessible, precise, and patient-friendly.
The wearable device measures hormones in interstitial fluid, offering real-time insights without the need for invasive blood draws. This innovation has the potential to benefit patients undergoing IVF, menopause management, or testosterone replacement therapy (TRT), as well as healthcare providers and pharmaceutical applications. In less than a year, the company has validated its DNA-based sensors across 98% of the human clinical range, positioning itself as a frontrunner in next-generation diagnostics.
Purpose of financing
With the newly secured funding, Level Zero Health aims to accelerate research and development to enhance its DNA-based hormone monitoring system, expand its team across the UK and US, and advance preparations for clinical trials while navigating regulatory approvals. Additionally, the company plans to introduce its product to the market, initially targeting B2B clinical applications.
CEO’s Insights
Ula Rustamova, CEO and co-founder of Level Zero Health, said:
“Our innovative remote monitoring technology marks an enormous leap forward in hormone testing, and this funding will enable us to bring this revolutionary solution to market. This breakthrough in health technology has come about in a relatively short amount of time, but already we are seeing strong demand from customers who recognise the benefits of hormone monitoring not only because it allows patients to skip invasive and inconvenient lab tests, but also because it captures critical data inaccessible before.”
Investor Perspective
Philip Kneis, investor at Redalpine and board member of Level Zero Health, shared his enthusiasm:
“Continuous hormone measurement is one of the holy grails of diagnostics, and as fundamental science transitions to engineering, we couldn’t be more excited to back Level Zero Health in their mission to transform hormone tracking with their novel biosensor – paving the way for a new era of personalised health management.”
Conclusion
By modernising hormone diagnostics, Level Zero Health is poised to redefine hormonal healthcare, offering patients and clinicians real-time access to critical hormonal data. With its innovative approach and ambitious roadmap, the company is set to lead the charge in personalised and precise hormone health solutions.
For updates, visit Level Zero Health on Linkedin.